Concord Biotech Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln M/SNSE
₹548.20
-8.20-1.47% (1D)
As on 20 Nov 2026 at 15:59
As of 20 Nov 2026 at 15:59, Concord Biotech Ltd is trading at ₹548.20. The 52-week range stands at ₹493.50–₹807.50, with a market cap of ₹11.47 thousand crore. At a P/E of 38.62 and a dividend yield of 0.69%, it is a mid-cap stock in the Pharmaceuticals sector.

CONCORDBIO Price Chart

Market Cap
₹11.47K Cr
PE Ratio
38.62
ROCE
18.83%

Concord Biotech Ltd Performance

Concord Biotech Ltd Fundamentals

Know More
Market Cap₹11.47K Cr
ROE14.13%
P/E Ratio (TTM)38.62
EPS (TTM)₹14.20
P/B Ratio5.50
Dividend Yield0.69%
Industry P/E91.72
Book Value₹99.71
Debt to Equity0.00
Face Value₹1

Concord Biotech Ltd Shareholding Pattern

Know More
Promoter44.1%
Foreign Institutions7.3%
Mutual Funds5.8%
Domestic Institutions5.2%
Public37.6%

Concord Biotech Ltd Financial Statements

Know More
No data for this view.

Concord Biotech Ltd Peer Comparison

Know More
StocksLTP(₹)Market Cap(Cr)52 Week Low-High(₹)
Sun Pharmaceutical Industries Ltd
₹1,885.10
-14.90(-0.78%)
4,52,298.61,583.7 - 2,046.9
Torrent Pharmaceuticals Ltd
₹4,698.80
87.80(+1.90%)
1,78,727.33,672.3 - 5,250.0
Dr Reddys Laboratories Ltd
₹1,390.50
-10.40(-0.74%)
1,16,144.51,101.0 - 1,414.9
Cipla Ltd
₹1,414.95
-3.55(-0.25%)
1,14,312.11,165.7 - 1,539.7
Lupin Ltd
₹2,010.00
11.20(+0.56%)
91,915.91,892.9 - 2,529.5

About Concord Biotech

Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat. In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid. In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat. It set up a joint venture in Japan to grow business in 2018. In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg. In 2020, Mycophenolate Sodium Tablets got launched in the US market. The Company introduced a new manufacturing unit at Limbasi, and commenced operations in July, 2021. As of March 31, 2022, the Company had 6 fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera, which were commercialized in 2000, 2021 and 2016, respectively. Their total annual installed fermentation capacity for APIs was 1,250 m3, as of March 31, 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. In August 2023, Company made an Initial Public Offer by issuing 20,925,652 Equity Shares aggregating to Rs 1551 Crores through Offer for Sale. The Company launched 21 new formulations products in 2025. Company commissioned a new injectable manufacturing facility at Valthera in FY25. It acquired a 75% equity stake in Stellon Biotech Inc., resulting in as a subsidiary incorporated in the United States in FY2026. Further, Concord Lifegen Limited has been incorporated as wholly owned subsidiary during 2026.

Parent Organisation—
Founded1984
Managing DirectorSUDHIR JAIRAM VAID
NSE SymbolCONCORDBIO

Concord Biotech Ltd Resistance and Support levels

R3567.40R2562.85R1560.05S1550.95S2548.15S3543.60548.20

Concord Biotech Ltd Technicals

Current Price
₹548.20 ₹8.20 (-1.47%)
Bearish
12
Bullish
0
  • 20 Day9.9%
  • 50 Day15.2%
  • 100 Day16.9%
  • 200 Day18.2%

Concord Biotech Ltd Latest News

View More
05 NOV 2026 | Thursday
Concord Biotech’s board approved a 1:1 bonus share allotment, effective November 4, 2026
27 OCT 2026 | Tuesday
Concord Biotech sets November 4, 2026, as record date for 1:1 bonus share issue
22 OCT 2026 | Thursday
Concord Biotech to review Q2 financial results at board meeting on October 27, 2026
07 OCT 2026 | Wednesday
Concord Biotech confirmed securities handling compliance with a certificate filed with Indian exchanges
28 SEPT 2026 | Monday
Concord Biotech halts share trading October 1st pending financial results declaration
19 SEPT 2026 | Saturday
Concord Biotech to consider bonus equity shares at board meeting on September 23, 2026
29 JUL 2026 | Wednesday
Concord Biotech to discuss results
08 JUL 2026 | Wednesday
Concord Biotech schedules AGM
25 JUN 2026 | Thursday
Concord Biotech's Unit II formulations unit successfully clears PPB and NDA inspection
25 JUN 2026 | Thursday
Concord Biotech's formulation facility clears regulatory inspections by Kenya's PPB & Uganda's NDA

2026

Quarterly ResultRelease dateCheck Latest financial
Board MeetingAnnounced
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial

Frequently asked questions

The share price of Concord Biotech Ltd is ₹548.20 as of 20 Nov 2026 at 15:59.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now